Recent mergers may hurt, not help, care coordination

The recently announced deals which could blur the lines between insurers and care providers—including the $66 billion purchase of Aetna by CVS Health and UnitedHealth’s Optum paying $4.9 billion for DaVita Medical Group—may not deliver the kind of “disruption” healthcare needs, Commonwealth Fund president David Blumenthal, MD, MPP wrote in Harvard Business Review.

The hope is when these new partnerships assume financial responsibility for the care they provide. The CVS-Aetna combination, Blumenthal wrote, would have to form relationships with or acquire larger providers like hospital or specialty clinics and then manage physicians or health care professionals.

“By adding another player to our already-fragmented health care system, the CVS-Aetna project could actually undermine coordination of services,” he wrote. “And while better care for complex patients is clearly part of the solution to our cost and quality problems, it may not be the systemic disruption that some are hoping for.”

The Optum-DaVita deal, however, may provide the kind of care coordination achieved by providers which also own health plans, like Kaiser Permanente and Intermountain Healthcare.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.